Source:http://linkedlifedata.com/resource/pubmed/id/10210142
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1999-6-16
|
| pubmed:abstractText |
To evaluate the safety of a plasmid DNA vaccine, tissue distribution studies in mice and safety studies in mice and rabbits were conducted with VCL-2510, a plasmid DNA encoding the gene for the malaria circumsporozoite protein from Plasmodium falciparum (PfCSP). After intramuscular administration, VCL-2510 plasmid DNA was detected initially in all of the highly vascularized tissues, but at later time points was found primarily in the muscle at the site of injection, where it persisted for up to 8 weeks. After intravenous administration, plasmid DNA initially distributed at a relatively low frequency to all the tissues examined except the gonads and brain. However, plasmid DNA rapidly cleared, and by 4 weeks postadministration could be detected only in the lung of one of six animals evaluated. In a safety study in mice, eight repeated intramuscular injections of VCL-2510 at plasmid DNA doses of 1, 10, and 100 microg had no adverse effects on clinical chemistry or hematology, and did not result in any organ pathology or systemic toxicity. In a safety study in rabbits, six repeated intramuscular injections of VCL-2510 at plasmid DNA doses of 0.15 and 0.45 mg had no discernible effects on clinical chemistry, hematology, or histopathology. No evidence of autoimmune-mediated pathology, anti-nuclear antibodies (ANA), or antibodies to dsDNA were observed in the mouse or rabbit studies.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1043-0342
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
20
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
741-58
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10210142-Age Factors,
pubmed-meshheading:10210142-Animals,
pubmed-meshheading:10210142-Dose-Response Relationship, Drug,
pubmed-meshheading:10210142-Electrophoresis, Agar Gel,
pubmed-meshheading:10210142-Evaluation Studies as Topic,
pubmed-meshheading:10210142-Female,
pubmed-meshheading:10210142-Genetic Vectors,
pubmed-meshheading:10210142-Histocytochemistry,
pubmed-meshheading:10210142-Injections, Intramuscular,
pubmed-meshheading:10210142-Malaria,
pubmed-meshheading:10210142-Male,
pubmed-meshheading:10210142-Mice,
pubmed-meshheading:10210142-Mice, Inbred ICR,
pubmed-meshheading:10210142-Plasmids,
pubmed-meshheading:10210142-Plasmodium falciparum,
pubmed-meshheading:10210142-Polymerase Chain Reaction,
pubmed-meshheading:10210142-Protozoan Proteins,
pubmed-meshheading:10210142-Rabbits,
pubmed-meshheading:10210142-Sex Factors,
pubmed-meshheading:10210142-Time Factors,
pubmed-meshheading:10210142-Tissue Distribution,
pubmed-meshheading:10210142-Vaccines, DNA
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits.
|
| pubmed:affiliation |
Vical, Inc., San Diego, CA 92121, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|